Every single one of the monthly Pricewatch UK features published by Generics Bulletin so far in 2024 has seen our Biggest Risers table led by at least two generic presentations that have experienced a treble-digit-percentage average price rise, meaning that a presentation’s trade price to UK independent pharmacists has more than doubled in the previous month.
UK Generic Price Spikes Ease In April
Pricewatch – April 2024
With UK shortages and price rises making headlines in early 2024, April’s generic pricing data suggested an easing of pricing increases, according to the latest figures from WaveData.
More from Generics
• By
Amid ongoing generic drug supply problems, Japan's government is to set up a new fund to support corporate investments geared towards manufacturing and consolidation.
• By
The US FDA has deemed certain CRO Raptim Research’s in vitro bioequivalence studies as “not acceptable” and raised concerns over its in vivo study methods. Will other agencies follow suit?
• By
Teva should not be able to overturn European fines imposed over a historical “pay-for-delay” arrangement covering Cephalon’s Provigil (modafinil), an advocate general of the CJEU has recommended.
• By
Alvotech has named two new key executives, while Biosimilars Canada has elected its 2025 leaders and the AAM has welcomed the new FDA commissioner in the US.
More from Market Intelligence
• By
Dementia treatment memantine saw the steepest rise in its UK trade price in November, according to the latest figures from WaveData.
• By
After a few months of steep UK price rises for apixaban generics, October saw a correction as average prices headed in the opposite direction, the latest figures from WaveData reveal.
• By
Generics of the schizophrenia treatment Latuda generated more than $4bn in savings a year after their 2022 approval, according to an FDA study.